1. Clinical Focus

3. Overview of TNBC

4. Current Treatment Landscape for TNBC

5. Early TNBC: Neoadjuvant and Adjuvant Therapies

6. Patient Case

7. Key Decision Point #1

8. Key Decision Point #2

9. Neoadjuvant Chemotherapy

10. Key Decision Point #2 (cont)

11. Key Decision Point #2 (cont)

12. Key Decision Point #3

13. pCR and Prognosis in the Adjuvant Setting

14. Back to the Patient Carboplatin -- To Add or Not to Add

15. Awaiting Data From the Ongoing NRG-BR003 Adjuvant Trial

16. Back to the Patient BRCA-Mutated TNBC

17. Adjuvant Platinum Therapy in Patients With BRCA-Positive Disease

18. Back to the Patient Residual Disease

19. Adjuvant Therapy for Residual Disease

20. CREATE-X DFS and OS Benefit for Capecitabine in TNBC

21. Challenges With Adjuvant Capecitabine

22. Ongoing Adjuvant Trials for Residual Disease

23. Metastatic TNBC

24. Approval of PARP Inhibitors for MBC

25. OlympIAD: Study Design

26. PARP Inhibition and Synthetic Lethality in Tumors With BRCA Mutations

27. OlympiAD: Olaparib Improves mPFS and ORR

28. OlympiAD Survival: Benefit Seen in First-Line Patients

29. OlympiAD: Safety and AEs

30. EMBRACA: Study Design

31. EMBRACA Primary Endpoint: PFS by Blinded Central Review

32. EMBRACA Interim OS Analysis

33. EMBRACA Safety: Selected AEs

34. MDACC Neoadjuvant Talazoparib Pilot Trial

35. Back to the Patient

36. IMpassion 130: Trial Design

37. IMpassion 130: PFS in ITT and PD-L1-Positive Subgroup

38. IMpassion 130: OS in ITT and PD-L1-Positive Subgroup

39. What About TNBC That is BRCA-Mutated and PD-L1-Positive?

40. Back to the Patient (cont)

41. EMBRACE Trial

42. Phase 3 Eribulin Study 301

43. Future Directions and Take-Home Points

44. IMMU-132: Sacituzumab Govitecan

45. AKT Inhibition

46. Take-Home Messages

47. Abbreviations

48. Abbreviations (cont)

49. Abbreviations (cont)

50. Abbreviations (cont)